I am  also the southern director of the American Working Collie Association

http://www.awca.net/index.htmNew Link here  

you are welcome to join

  I am  also the southern director of the American Working Collie Association  Link here

Windy

is a daughter of the great Mason and Natalie of Northern Classic Collies. Windy lived with us since a puppy having fun in training classes and having many wonderful healthy puppies that went on to families and careers in therapy and events.

Windy is the dam of Breezy, Her Majesty,

From: "Bentjen, Steve" <steveb@vetmed.wsu.edu>

To: <goldencollies@yahoo.com>

Date: Fri, 16 Nov 2007 11:16:24 -0800

Subject: MDR-1 GENOTYPE RESULTS

MDR1* GENOTYPING RESULTS                           11/16/2007                                        MDR1- 8379     

Denise Schroeder  

Nevis, MN     

MDR1 TEST RESULTS FOR:

Dog Name:       Windy

Dog Breed:      Collie

Test Result:     Normal/Normal

Explanation of test results:

Normal/Normal- These dogs do not carry the mutation, and will not pass on the mutation to their offspring.  These dogs would not be expected to experience unexpected adverse drug reactions to normal doses of ivermectin, loperamide (Imodium®), and some anticancer drugs.

Mutant/Mutant- These dogs carry the mutation and can not pass on a normal gene to their offspring.    These dogs would be expected to experience toxicity after normal doses of loperamide (Imodium®), some anticancer drugs, and high doses of ivermectin (greater than 50 micrograms per kilogram).

Mutant/Normal- These dogs carry the mutation and may pass on the mutant gene to their offspring.  These dogs

may experience toxicity after normal doses of loperamide (Imodium®), some anticancer drugs, and high doses of ivermectin (greater than 50 micrograms per kilogram).

A current list of problem drugs for dogs with the MDR1 mutation may be found at this web address:

http://www.mdr1test.com  Steve Bentjen

Veterinary Clinical Pharamacology Laboratory Manager

* PCR for this service is performed pursuant to an agreement with Roche Molecular Systems, Inc.